News

The study met its primary endpoint in this cohort as measured by a change in total chloride response following 4 weeks of treatment with QR-010. In the compound

In April 2015, the FDA granted orphan drug status to ADS-5102 for this indication.  Adamas Pharmaceuticals chairman and CEO Gregory Went said: "The ADS-5102 NDA submission represents a major milestone

The phase III randomized, double-blind, parallel arm, multiple dose, active comparator study also met secondary endpoints. The study included 645 patients diagnosed with moderate to severe active RA

Patients who received apatorsen treatment experienced a 20% reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 95% CI: 0.65-0.98; p=0.078). The primary analysis was

Professor Eicke Latz, Director of the Institute, and Professor Matthias Geyer, Department Head for Structural Immunology, are scientific Co-founders of IFM Therapeutics. IFM Therapeutics’ scientific mission is to

The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of

The companies did not disclose the value of the expanded collaboration, which features a new, three-year research partnership. Under the partnership, the companies will develop cognitive technologies to

The joint project will see Fimbrion and the Discovery Partnerships with Academia (DPAc) team at GSK focus on the preclinical development of a class of mannose-containing small molecule

Betrixaban, an FDA Fast Track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant. John Curnutte, M.D. Ph.D., executive vice president, research and development at Portola, said: